Grifols (GIFLF) Construction in Progress (2021 - 2023)
Grifols' (GIFLF) quarterly Construction in Progress came in at $31.3 million in Q4 2023, up 27.55% on a YoY basis from $24.5 million in Q4 2022, and up 27.55% quarter-over-quarter from $24.5 million in Q4 2022.
Analysis
Grifols (GIFLF) Construction in Progress (2021 - 2023) Analysis & Trends
Grifols (GIFLF) has reported Construction in Progress for 3 consecutive years, with $31.3 million the latest figure, recorded in Q4 2023.
- For the quarter ending Q4 2023, Construction in Progress rose 27.55% year-over-year to $31.3 million; the trailing twelve-month figure through Dec 2023 stood at $31.3 million (up 27.55% YoY), and the FY2023 full-year result was $31.3 million, up 7.59% from the prior year.
- Construction in Progress improved to $31.3 million in Q4 2023 per GIFLF's latest filing, from $24.5 million in the prior quarter.
- Across five years, Construction in Progress topped out at $31.3 million in Q4 2023 and bottomed at $24.5 million in Q4 2022.
- Historically, Construction in Progress has averaged $27.8 million across 3 years, with a median of $27.5 million in 2021.
- The sharpest annual moves came in 2022 and 2023: Construction in Progress declined 10.82% in 2022, then grew 27.55% in 2023.
- Over 3 years, Construction in Progress stood at $27.5 million in 2021, then dropped by 10.82% to $24.5 million in 2022, then advanced by 27.55% to $31.3 million in 2023.
- According to Business Quant data, Construction in Progress over the past three periods registered $31.3 million, $24.5 million, and $27.5 million for Q4 2023, Q4 2022, and Q4 2021 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Construction in Progress (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 203.97 Bn | 189.99 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 178.74 Bn | 175.56 Bn | 6.22 Bn | - |
| 3 | Vertex Pharmaceuticals | 130.73 Bn | 122.88 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 80.42 Bn | 72.42 Bn | 3.93 Bn | - |
| 5 | Argenx Se | 60.40 Bn | 55.21 Bn | 1.37 Bn | - |
| 6 | Moderna | 57.65 Bn | 52.52 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 33.37 Bn | 30.07 Bn | 992.69 Mn | - |
| 8 | Biogen | 32.15 Bn | 30.86 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 29.58 Bn | 29.58 Bn | 1.16 Mn | - |
| 10 | Grifols | 7.54 Bn | 9.09 Bn | 3.33 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2023 | 31.27 Mn |
| Dec 31, 2022 | 24.51 Mn |
| Dec 31, 2021 | 27.49 Mn |